RY 174.39 2.4016% SHOP 149.115 2.5974% TD-PFM 24.63 -0.0811% TD-PFL 24.7 0.2028% TD 78.325 0.1214% ENB 60.6 1.3039% BN 80.4 1.9787% TRI 226.27 0.7525% CNQ 48.285 2.2771% CP 104.53 1.6038% CNR 151.74 1.5459% BMO 132.69 0.9203% BNS 78.845 0.1715% CSU 4600.2002 2.157% CM 91.15 0.474% MFC 45.79 1.6878% ATD 78.38 1.5285% NGT 60.14 0.0499% TRP 70.15 1.977% SU 57.44 0.5954%
Last update at 2024-11-21T19:37:00Z
Zacks.com featured highlights Tilray, Consol Energy and Apogee Enterprises
Mon 21 Oct 24, 09:39 AMWeekly Roundup on the Cannabis Sector & Psychedelic Sector 10-14-24
Mon 14 Oct 24, 12:51 AMAre Investors Undervaluing Tilray Brands, Inc. (NASDAQ:TLRY) By 28%?
Fri 11 Oct 24, 10:55 AMTilray Brands First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Fri 11 Oct 24, 10:54 AMTilray Brands, Inc. (TLRY) Reports Q1 Loss, Lags Revenue Estimates
Thu 10 Oct 24, 12:10 PMTilray Brands Reports Q1 2025 Financial Results
Thu 10 Oct 24, 11:00 AM20 States with the Highest Weed Consumption in the US
Mon 07 Oct 24, 11:05 PMInsights Into Tilray Brands (TLRY) Q1: Wall Street Projections for Key Metrics
Mon 07 Oct 24, 01:15 PMTilray Brands Launches Charlotte’s Web™ CBD Gummies in Canada
Mon 07 Oct 24, 11:00 AM| Breakdown | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
| Income before tax | -1450.18100M | -440.67400M | -344.98600M | -58.19245M | -11.56319M |
| Minority interest | -9.65600M | -42.66900M | 6.24M | 26.96M | 21.02M |
| Net income | -1443.00000M | -434.13200M | -336.01400M | -61.01639M | -12.19438M |
| Selling general administrative | 230.94M | 162.80M | 111.58M | 88.30M | 70.83M |
| Selling and marketing expenses | - | 65.86M | 44.12M | 29.92M | 20.67M |
| Gross profit | 146.96M | 116.82M | 123.18M | 137.68M | 55.74M |
| Reconciled depreciation | 130.15M | 115.19M | 67.83M | 49.27M | 22.94M |
| Ebit | - | 153.29M | -4.94700M | 51.48M | -2.59941M |
| Ebitda | -1306.44500M | 268.49M | 30.27M | 67.16M | 14.36M |
| Depreciation and amortization | - | 115.19M | 35.22M | 15.68M | 16.95M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -178.14700M | 153.29M | -4.94700M | 51.48M | -2.59941M |
| Other operating expenses | - | 856.92M | 581.64M | 389.07M | 222.44M |
| Interest expense | 13.59M | 39.68M | 30.90M | 24.78M | 5.75M |
| Tax provision | -7.18100M | -6.54200M | -5.60200M | -8.45000M | -4.45100M |
| Interest income | 33.02M | 11.74M | 26.05M | 27.98M | 16.34M |
| Net interest income | -13.58700M | -27.94400M | -27.97700M | -26.34700M | 6.58M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | -6.54200M | -8.97200M | 2.82M | 0.63M |
| Total revenue | 627.12M | 628.37M | 513.09M | 391.00M | 175.25M |
| Total operating expenses | 805.27M | 345.37M | 191.74M | 135.75M | 102.94M |
| Cost of revenue | 480.16M | 511.56M | 389.90M | 253.31M | 119.50M |
| Total other income expense net | -1258.44700M | -593.96900M | -340.03900M | -109.67579M | -8.96378M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -1443.00000M | -434.13200M | -336.01400M | -84.63400M | -16.49900M |
| Net income applicable to common shares | - | -476.80100M | -367.42100M | -102.54000M | -25.03700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-05-31 | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 |
| Total assets | 4221.66M | 4307.26M | 5449.69M | 6025.36M | 1801.23M |
| Intangible assets | 915.47M | 973.78M | 1277.88M | 1605.92M | 261.73M |
| Earning assets | - | - | - | - | - |
| Other current assets | 31.33M | 37.72M | 46.79M | 48.92M | 51.42M |
| Total liab | 778.49M | 977.32M | 1008.33M | 1560.05M | 475.89M |
| Total stockholder equity | 3442.91M | 3315.69M | 4398.81M | 4459.07M | 1306.74M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 18.25M | 18.04M | 119.09M | 293.93M | 9.24M |
| Common stock | 0.08M | - | 0.05M | 0.05M | 1331.54M |
| Capital stock | 0.08M | 0.07M | 0.05M | 0.05M | 1331.54M |
| Retained earnings | -2660.48800M | -2415.50700M | -962.85100M | -486.05000M | -44.13260M |
| Other liab | - | - | 196.83M | 269.75M | 48.45M |
| Good will | 2008.88M | 2008.84M | 2641.30M | 2832.79M | 445.50M |
| Other assets | - | - | 111.51M | 8.29M | 7.86M |
| Cash | 228.34M | 206.63M | 415.91M | 488.47M | 358.47M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 299.17M | 432.98M | 280.34M | 401.24M | 122.84M |
| Current deferred revenue | 136.56M | - | - | 155.11M | 0.65M |
| Net debt | 158.98M | 373.14M | 207.90M | 450.19M | -58.14775M |
| Short term debt | 38.96M | - | 92.65M | 49.60M | 7.44M |
| Short long term debt | 33.87M | 221.84M | 85.95M | 45.34M | 9.00M |
| Short long term debt total | 387.32M | - | 623.81M | 938.66M | 300.32M |
| Other stockholder equity | 6146.81M | - | 5382.37M | 4792.41M | 20.24M |
| Property plant equipment | - | - | 600.50M | 668.97M | 426.06M |
| Total current assets | 677.71M | 773.03M | 803.50M | 883.61M | 651.22M |
| Long term investments | 7.86M | 12.37M | 15.00M | 25.79M | 27.02M |
| Net tangible assets | - | - | 479.62M | 20.36M | 537.33M |
| Short term investments | 32.18M | 241.90M | - | - | 0.00000M |
| Net receivables | 101.69M | 86.23M | 95.28M | 89.79M | 50.77M |
| Long term debt | 287.94M | 357.93M | 519.83M | 306.26M | 430.21M |
| Inventory | 252.09M | 200.55M | 245.53M | 256.43M | 190.56M |
| Accounts payable | 105.39M | 70.82M | 68.60M | 57.71M | 110.12M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -43.49900M | - | -20.76400M | 152.67M | -0.91488M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5.39M | 0.22M | 111.51M | 8.29M | 0.00000M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3543.95M | 3534.23M | 4646.19M | 5141.75M | 1150.01M |
| Capital lease obligations | 65.51M | 10.36M | 18.03M | 58.21M | 7.14M |
| Long term debt total | - | - | - | 870.59M | 444.36M |
| Breakdown | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-05-31 | 2022-05-31 | 2021-05-31 | 2020-05-31 | 2019-05-31 |
| Investments | -285.11100M | -21.53300M | 8.43M | 33.94M | 47.29M |
| Change to liabilities | - | -44.65200M | 14.63M | 47.32M | -0.14500M |
| Total cashflows from investing activities | - | -21.53300M | 46.10M | -69.94600M | -134.51700M |
| Net borrowings | - | -123.54600M | 45.51M | 52.29M | 356.06M |
| Total cash from financing activities | 70.16M | 128.20M | 124.31M | 125.40M | 535.51M |
| Change to operating activities | - | 4.47M | -6.77200M | -10.89900M | 4.32M |
| Net income | -1443.00000M | -434.13200M | -336.01400M | -61.01639M | -12.19438M |
| Change in cash | -209.27700M | -72.55700M | 127.82M | -38.62458M | 362.94M |
| Begin period cash flow | 415.91M | 488.47M | 360.65M | 397.09M | 44.15M |
| End period cash flow | 206.63M | 415.91M | 488.47M | 358.47M | 407.09M |
| Total cash from operating activities | 7.91M | -177.26200M | -44.71700M | -96.43061M | -41.09756M |
| Issuance of capital stock | 129.59M | 262.51M | 102.55M | 71.90M | 181.76M |
| Depreciation | 130.15M | 154.59M | 67.83M | 35.52M | 16.95M |
| Other cashflows from investing activities | - | - | 3.33M | 19.40M | -8.28000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -12.93400M | -45.74900M | -35.28600M | -90.25428M | -29.17443M |
| Change to account receivables | 4.17M | -5.84200M | -23.51200M | -24.73415M | 9.21M |
| Sale purchase of stock | -1.18900M | - | 220.20M | 111.52M | 228.65M |
| Other cashflows from financing activities | - | -1.36100M | 87.38M | 63.07M | 362.16M |
| Change to netincome | - | 236.72M | 325.73M | 45.08M | -21.75100M |
| Capital expenditures | 20.80M | 34.06M | 38.87M | 95.47M | 152.23M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 14.40M | -91.77100M | -50.93500M | -82.95760M | -15.88396M |
| Stock based compensation | 39.59M | 35.99M | 17.35M | 16.22M | 19.28M |
| Other non cash items | 258.59M | 185.59M | 281.92M | -2.23709M | -46.22690M |
| Free cash flow | -12.89400M | -211.32600M | -83.59100M | -191.90019M | -193.32594M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TLRY Tilray Inc |
0.03 1.38% | 1.83 | - | 1000.00 | 2.17 | 0.36 | 1.69 | -2.299 |
| BHC Bausch Health Companies Inc |
-0.11 0.96% | 11.37 | - | 2.23 | 0.50 | 18.74 | 2.56 | 9.13 |
| CURA Curaleaf Holdings Inc. |
-0.175 5.93% | 2.77 | - | 138.89 | 1.62 | 1.66 | 1.73 | 10.18 |
| CRON Cronos Group Inc |
0.06 2.15% | 2.85 | - | - | 10.18 | 0.70 | 0.02 | -1.9458 |
| WEED Canopy Growth Corp |
0.22 4.17% | 5.49 | - | - | 2.77 | 1.22 | 3.58 | -1.5049 |
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner's High Brewing Company, Happy Flower, and Fresh Hemp Foods brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
265 Talbot Street West, Leamington, ON, Canada, N8H 5L4
| Name | Title | Year Born |
|---|---|---|
| Mr. Irwin David Simon | Pres, CEO & Chairman | 1958 |
| Mr. Carl A. Merton CA, CBV, CPA | CFO & Principal Accounting Officer | 1970 |
| Mr. Mitchell S. Gendel | Global Gen. Counsel & Corp. Sec. | 1966 |
| Mr. James R. Meiers | Sr. VP of U.S. Operations | 1958 |
| Ms. Denise Menikheim Faltischek | Chief Strategy Officer & Head of International | 1973 |
| Mr. Lloyd Brathwaite | Chief Information Officer | NA |
| Mr. Roger Savell | Chief Admin. Officer | NA |
| Mr. John B. Sadler | VP of Investor Relations | NA |
| Ms. Dara S. Redler | Interim Chief Legal Officer & Corp. Sec. | NA |
| Mr. Bernard Yeung | Sr. VP of Sales & Marketing | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...